10. September 2024 – Walder Wyss advised the shareholders of Saiba Animal Health AG in the sale of all shares to the biopharmaceutical giant Boehringer Ingelheim. Saiba Animal Health is focused on the development of novel therapeutic medicines to address chronic diseases in pets using its innovative technology platform with its first-of-its-kind therapeutic vaccine approach designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain.

The Walder Wyss team was led by Iliana Djagova (Counsel, M&A), Maurus Winzap (Partner, Tax) and Florian Gunz Niedermann (Partner, M&A) and further included Roger Staub (Partner, IP), Felix Tuchschmid (Associate, IP), Lucas Maurer (Associate, M&A), Janine Corti (Counsel, Tax), Alice Vorburger (Managing Associate, M&A), Carmen Stetter (Junior Lawyer, M&A) and Luca Bohnenblust (Junior Lawyer, M&A).